First primary breast cancer | Cases, N (%) | Controls, N (%) | RRa (95% CI) |
---|---|---|---|
Histology | |||
Non-lobular | 1338 (88) | 1986 (90) | 1.0 (ref.) |
Lobular | 179 (12) | 223 (10) | 1.3 (1.0, 1.6) |
Unknown | 4 (0) | 3 (0) | |
Grade | |||
Well | 248 (16) | 338 (15) | 1.0 (ref.) |
Moderate | 417 (27) | 688 (31) | 0.8 (0.7, 1.1) |
Poor/undifferentiated | 503 (33) | 640 (29) | 1.1 (0.8, 1.4) |
Unknown | 353 (23) | 546 (25) | |
Stage | |||
Localized | 1061 (70) | 1442 (65) | 1.0 (ref.) |
Regional | 448 (29) | 759 (34) | 1.0 (0.9, 1.2) |
Unknown | 12 (1) | 11 (1) | |
Lymph node status | |||
Negative | 1045 (69) | 1426 (64) | 1.0 (ref.) |
Positive | 438 (29) | 751 (34) | 1.0 (0.8, 1.2) |
No nodes sampled | 22 (2) | 26 (1) | 1.3 (0.7, 2.4) |
Unknown | 16 (1) | 9 (0) | |
Tumor size | |||
≤10 mm | 335 (22) | 510 (23) | 1.0 (ref.) |
>10 to ≤20 mm | 595 (39) | 913 (41) | 1.1 (0.9, 1.3) |
>20 mm | 477 (31) | 662 (30) | 1.1 (0.9, 1.4) |
Inflammatory | 6 (0) | 2 (0) | |
Unknown | 108 (7) | 125 (6) | |
ER status | |||
Positive | 797 (52) | 1254 (57) | 1.0 (ref.) |
Negative | 467 (31) | 561 (25) | 1.3 (1.1, 1.6) |
Other/unknownb | 257 (17) | 397 (18) | |
PR status | |||
Positive | 687 (45) | 1083 (49) | 1.0 (ref.) |
Negative | 442 (29) | 549 (25) | 1.2 (1.0, 1.5) |
Other/unknownb | 392 (26) | 580 (26) | |
Joint ER/PR status | |||
ER+/PR+ | 621 (41) | 958 (43) | 1.0 (ref.) |
ER+/PR- | 85 (6) | 142 (6) | 1.0 (0.7, 1.4) |
ER-/PR- | 352 (23) | 387 (18) | 1.4 (1.1, 1.7) |
Other/unknownb,c | 463 (30) | 725 (33) | |
HER2 statusd | |||
Negative | 207 (25) | 222 (27) | 1.0 (ref.) |
Positive | 53 (7) | 63 (8) | 0.8 (0.5, 1.3) |
Unknownb | 553 (68) | 528 (65) | |
Triple-negatived | |||
No | 514 (63) | 579 (71) | 1.0 (ref.) |
Yes | 59 (7) | 40 (5) | 1.3 (0.8, 2.2) |
Other/unknownb | 240 (30) | 194 (24) |